Pharmaceutical combination

A compound and fragment-binding technology, applied in the field of medicine, can solve problems such as poor curative effect, survival rate less than 30%, and insignificant benefit

Pending Publication Date: 2021-10-12
JIANGSU HENGRUI MEDICINE CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compared with single-drug sequential therapy, the curative effect (ORR/PFS) of combined chemotherapy will be improved, but the toxicity is greater, the survival time is still limited, and the OS benefit is not obvious
A number of clinical studies have shown that pa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Inclusion criteria:

[0086] 1. Invasive triple-negative breast cancer confirmed by histology (specific definition: immunohistochemical detection of ER<1% tumor cells positive is defined as ER negative, PR<1% tumor cells positive is defined as PR negative, HER20-1+ or HER2 is ++ but negative by FISH or CISH, without amplification, defined as HER2 negative);

[0087] 2. Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent and metastatic breast cancer;

[0088] 3. Refractory triple-negative breast cancer (existing treatments have failed), specific definition: common chemotherapy drugs that can be obtained in China include anthracyclines, taxanes, platinum, capecitabine, gemcitabine and vinorelbine , The above-mentioned commonly used chemical drug treatment fails, the patient's condition has not been effectively controlled before enrollment, and the condition is in progress.

[0089] Dosing regimen (every 4 weeks):

[0090] Drug A, PD-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure relates to pharmaceutical combinations. Specifically, the invention provides application of a PD-1 antibody combined with paclitaxel and a VEGFR inhibitor such as apatinib in preparation of drugs for treating triple negative breast cancer, the combined treatment scheme shows better disease control rate and objective response rate, embodies a synergistic effect of combined medication, and significantly improves the curative effect of immunotherapy.

Description

technical field [0001] The disclosure belongs to the field of medicine and relates to drug combinations, in particular to the use of a PD-1 antibody or an antigen-binding fragment thereof in combination with a taxane compound and a VEGFR inhibitor in the preparation of a drug for treating triple-negative breast cancer. Background technique [0002] Breast cancer has the highest incidence among female cancers in China and is on the rise. It is a common malignant tumor that endangers women's health. In China, according to the data collected by the National Cancer Registry Center in 2017, there were approximately 279,000 new female breast cancer cases in 2014, with an incidence rate of 41.82 / 100,000, ranking first among female malignant tumors; approximately 66,000 deaths occurred, The mortality rate is 9.9 / 100,000, and the age of onset is younger than that in western countries. Breast cancer is the sum of a class of diseases, which can be divided into at least four molecular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K31/337A61K31/444A61K45/00A61K47/42A61P35/00
CPCA61K39/39558A61K31/337A61K31/444A61K45/00A61K47/42A61P35/00A61K2039/505A61K2300/00
Inventor 邹建军张晓静朱晓宇
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap